Vertex gains 55% on surprising interim data from Kalydeco combo in cystic fibrosis
This article was originally published in Scrip
Vertex Pharmaceuticals, which has already succeeded in serving a niche population in cystic fibrosis with its recently approved drug Kalydeco (ivacaftor), has now opened the way to a much broader market in cystic fibrosis by pairing Kalydeco with the experimental agent VX-809. Interim results of a Phase II trial showed that the combination significantly improved lung function in adults who have two copies (homozygous) of the F508del cystic fibrosis transmembrane conductance regulator (CFTR) gene.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.